Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy
Asia-Pacific Journal of Clinical Oncology · 2024
DOI: 10.1111/ajco.13959 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2024. Verfasst von Sung Hee Lim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms, COVID-19 Vaccines, Antibodies, Viral. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Soonchunhyang University Bucheon Hospital Research Fund.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
This study examined the serum antibody response of coronavirus disease 2019 (COVID‐19) vaccines in solid and hematologic cancer patients undergoing chemotherapy. Levels of various inflammatory cytokines/chemokines after full vaccination were analyzed.
Methods
Forty‐eight patients with solid cancer and 37 with hematologic malignancy who got fully vaccinated either with severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) or vector vaccines or their combination were included. After consecutively collecting blood, immunogenicity was assessed by surrogate virus neutralization test (sVNT), and cytokine/chemokines were evaluated by Meso Scale Discovery assay.
Results
Seropositivity and protective immune response were lower in patients with hematologic cancer compared to those with solid cancers, regardless of vaccine type. Significantly lower sVNT inhibition was observed in patients with hematologic cancer (mean [SD] 45.30 [40.27] %) than in those with solid cancer (mean [SD] 61.78 [34.79] %) ( p = 0.047). Heterologous vector/mRNA vaccination was independently and most markedly associated with a higher sVNT inhibition score ( p < 0.05), followed by homologous mRNA vaccination. The mean serum levels of tumor necrosis factor α, macrophage inflammatory protein (MIP)‐1α, and MIP‐1β were significantly higher in patients with hematologic cancers compared to those with solid cancers after the full vaccination. In 36 patients who received an additional booster shot, 29 demonstrated increased antibody titer in terms of mean sVNT (%) (40.80 and 75.21, respectively, before and after the additional dose, p < 0.001).
Conclusion
Hematologic cancer patients receiving chemotherapy tended to respond poorly to both COVID‐19 mRNA and vector vaccines and had a significantly lower antibody titer compared to those with solid cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
Förderung
- Soonchunhyang University Bucheon Hospital Research Fund
Zitieren
APA
Lim, S. H., Choi, S. H., Ji, Y. S., Kim, S. H., Kim, C. K., Yun, J., & Park, S. K. (2024). Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13959
Vancouver
Lim SH, Choi SH, Ji YS, Kim SH, Kim CK, Yun J, et al. Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. Asia-Pacific Journal of Clinical Oncology. 2024. doi:10.1111/ajco.13959
BibTeX
@article{Lim2024,
author = {Lim, Sung Hee and Choi, Seong Hyeok and Ji, Young Sok and Kim, Se Hyung and Kim, Chan Kyu and Yun, Jina and Park, Seong Kyu},
title = {Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2024},
doi = {10.1111/ajco.13959}
}
EUVIMED